[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ablation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,76,99,123,149,182,194,228,255,284,306],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100053386","a-cohort-study-of-combined-cryoablation-and-thermal-ablation-for-non-surgical-treatment-of-breast-cancer-patients-100053386",false,"NCT07238894","A Cohort Study of Combined Cryoablation and Thermal Ablation for Non-surgical Treatment of Breast Cancer Patients","Peking University People's Hospital Breast Surgery Department","Inclusion Criteria:\n\n* 1\\) Aged 18 or above; 2) Breast cancer confirmed by core needle biopsy; 3) Tumor lesions clearly visible on ultrasound; 4) No contraindications for cryoablation such as coagulation disorders; 5) Presence of reasons unsuitable for conventional surgical resection: patient's condition cannot tolerate general anesthesia or surgical treatment; due to unresectable and\u002For metastatic disease; patient refuses surgery, etc.; 6) Agree to undergo ablation surgery and sign the consent form.\n\nExclusion Criteria:\n\n* 1\\) Missing clinical and pathological data (such as imaging and pathological materials); 2) Pregnant or lactating women; 3) Known allergies, intolerances, or contraindications to cryotherapy (such as cryoglobulinemia, presence of implanted electronic devices); 4) Vulnerable populations, including those with neurological disorders, cognitive impairments, critically ill patients, etc.",true,"FEMALE","18 Years","80 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Although surgical resection is the gold standard for early breast cancer treatment, some patients cannot tolerate surgery due to medical conditions or refuse surgical treatment for cosmetic reasons. In recent years, the rapid development of ablation technology has provided new directions for breast cancer patients who are not suitable for surgical treatment. Ablation uses high or low temperatures to deactivate lesions or tissues, which are gradually absorbed by the body, achieving local treatment purposes. Its safety and efficacy have been preliminarily confirmed. As an advanced minimally invasive medical device independently developed in China, the combined cryo-thermal ablation system treats tumors using a combined mode of deep cryogenic freezing and high-intensity heating. It has been approved for ablation treatment of various solid tumors including lung cancer, pancreatic cancer, kidney cancer, prostate cancer, breast cancer, bone and soft tissue sarcomas.\n\nThis project proposes a prospective cohort design, based on the breast disease cohort database of Peking University People's Hospital Breast Center. It will enroll patients pathologically diagnosed with breast cancer, determined unsuitable for surgical treatment, and have received combined cryo-thermal ablation. The registered data will be used to evaluate the effectiveness and safety of percutaneous ultrasound-guided cryo-thermal composite ablation in this population.",[28,29],"Ablation","Breast Cancer",[31],"Combined Cryoablation and Thermal Ablation","RECRUITING","2026-07-10",{"date":35,"type":36},"2026-07-13","ACTUAL",{"date":38,"type":36},"2026-03-03",{"date":40,"type":22},"2028-10-01",{"name":42,"class":43},"Peking University People's Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100615021","prospective-evaluation-of-the-pulse-biosciences-npulse-vybrance-percutaneous-electrode-system-100615021","NCT07287176","Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System","Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System in Symptomatic Benign Thyroid Nodules (PRECISE-BTN) Study","PRECISE-BTN","Inclusion Criteria:\n\n* Participant is willing and able to provide voluntary, written informed consent to participate in this study and from whom written informed consent has been obtained\n* Participants must be willing and able to comply with study procedures including all follow-up visits\n* Selected nodule is amenable to trans-isthmus approach\n* Nodule is confirmed as benign based on results from one or more of the following diagnostic tests:\n\n  1. (Bethesda II) on at least 2 ultrasound guided fine needle aspirations (FNA) or core needle biopsy (CNB);\n  2. A single benign diagnosis of FNA or CNB when the nodule has benign ultrasound features \\[American College of Radiology (ACR) Thyroid Imaging Reporting \\& Data System \\[TI-RAD\\] TR 1-3, American Thyroid Association \\[ATA\\] very low suspicion\\];\n  3. Candidate has a hyperfunctional nodule following 1 ultrasound guided FNA or CNB with or without molecular testing; or\n  4. Benign (Bethesda III or IV) with two biopsies in addition to molecular testing confirming benign diagnosis\n* Selected nodule is \\\u003C80.0 ml\n* Participant has normal vocal cord mobility by ultrasound evaluation\n* Participant has presence of compression symptoms, cosmetic concerns or anxiety for which participant requests treatment of the benign thyroid nodule\n* Participant has a solitary thyroid nodule or dominating nodule that is well-defined in multinodular goiter\n\nExclusion Criteria:\n\n* Participant has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter defibrillator)\n* Participant has cystic nodules (\\\u003C 70% solid components)\n* Participant has calcified nodules\n* Participant is known to be immune compromised\n* Participant had previous neck irradiation\n* Participant has abnormal cervical lymph nodes present during screening visit examination\n* Participant has history of familial thyroid cancer in more than two first-degree relatives\n* Selected nodule previously treated with radiofrequency ablation or ethanol. This does not apply to nodules previously treated with nanosecond Pulsed Field Ablation (nsPFA)\n* Participants currently suffering from a hematological disease or bleeding tendency\n* Selected nodule likely to be in contact with the recurrent laryngeal nerve on ultrasound evaluation\n* Participant has a history of uncontrolled cardiac arrhythmia, uncontrolled hypertension, chronic liver disease or chronic kidney disease (Stage 4-5), or recent history of myocardial infarction or structural heart disease as determined by the Investigator\n* Participant has abnormal contralateral vocal cord function\n* Anesthesia drug allergies\n* Participant is pregnant at the time of screening or within 30 days prior to enrollment\n* Participant has any condition or situation which, in the Investigator's opinion, puts the participant at significant risk, could confound the study results, or may interfere significantly with the participant's participation in the study\n* Use of any investigational device or drug within 30 days prior to enrollment that may confound the results of this study","ALL","22 Years",{"count":56,"type":22},100,[25],"The primary objective of this study is to reproduce in a multi-center study results obtained during the feasibility First-In-Human (FIH) study with Prof. Stefano Spiezia, MD (Ospedale del Mare, Naples, Italy) and to monitor additional thyroid-related symptoms and impact of patients quality of life post-ablation using a validated QoL questionnaire.",[60,61,28],"Thyroid Nodule","Thyroid Goiter",[63,64],"nsPFA","Pulsed Field Ablation","2026-04-13",{"date":67,"type":36},"2026-04-15",{"date":69,"type":36},"2025-08-21",{"date":71,"type":22},"2027-06-30",{"name":73,"class":74},"Pulse Biosciences, Inc.","INDUSTRY",3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100630162","ablation-compare-with-surgery-for-early-breast-cancer-100630162","NCT07484087","Ablation Compare With Surgery for Early Breast Cancer","Prospective, Randomized Controlled Study Comparing Cryo-Thermal Ablation With Traditional Breast-Conserving Surgery in HR-Positive, HER2-Negative Early-Stage Breast Cancer","Inclusion Criteria:\n\n* 1.Age ≥50 Years 2.Unifocal disease (single tumor) confirmed by ultrasound, MRI, or mammography. Ultrasound visibility: Essential for precise intraoperative ablation targeting. 3.Pathologically Confirmed Invasive Ductal Carcinoma (IDC)。Diagnostic Method: Core needle biopsy (CNB) confirming IDC.\n\n  4.Histologic Grade: G1 or G2; ER\u002FPR-positive and HER2-negative. 5.TNM stage: IA. Tumor Size: ≤2 cm; Lymph Node Status: Clinically \\& radiologically negative (no palpable\u002Fimaging-detected axillary involvement).\n\n  6.Written consent for clinical trial participation and acceptance of random assignment\n\nExclusion Criteria:\n\n* 1.Extensive intraductal component (EIC) suggested by imaging or pathology. 2.Invasion of adjacent skin or muscle. 3.Prior anticancer treatment for the current disease, including but not limited to chemotherapy, endocrine therapy, targeted therapy, or immunotherapy. 5.Refusal to undergo breast-conserving surgery. 6.Pregnancy or lactation. 7.Previous radiotherapy to the affected breast or other contraindications to radiotherapy. 8.Concurrent untreated malignancies or severe systemic diseases， 9.Known allergy, intolerance, or contraindications to cryotherapy (e.g., cryoglobulinemia, implanted electronic devices). 10.Inability to comply with follow-up or refusal of adjuvant therapy. 11.Vulnerable populations, including individuals with neurological disorders, cognitive impairment, or critical illness.","50 Years",{"count":85,"type":22},264,[25],"Breast-conserving surgery has been widely used in clinical practice, but surgical incisions still impact postoperative patient satisfaction with breast appearance. The development of tumor ablation technologies has introduced new possibilities for breast cancer surgical treatment. The hybrid cryo-thermal ablation system, an advanced minimally invasive tumor treatment device independently developed in China, employs a combined approach of deep cryoablation and high-intensity heating for therapy and has been approved for treating solid tumors, including breast cancer.\n\nThis study is a prospective, single-center, randomized controlled trial. Eligible patients with newly diagnosed early-stage breast cancer treated at the Breast Center of Peking University People's Hospital will be enrolled and randomized in a 1:1 ratio to receive either hybrid cryo-thermal ablation (experimental group) or breast-conserving surgery (control group). Data collected will include:\n\nBaseline clinicopathological characteristics， Surgical details (operation time, intraoperative\u002Fpostoperative complications, etc.)， Peripheral blood lymphocyte distribution， Treatment efficacy (ipsilateral breast tumor recurrence rate, disease-free survival, overall survival)， Aesthetic outcomes (BREAST-Q score).\n\nPrimary endpoint:\n\nIpsilateral breast local recurrence rate，\n\nSecondary endpoints:\n\nSafety (incidence of adverse events assessed by CTCAE criteria)， Disease-free survival and overall survival， Quality of life assessment (breast satisfaction)，\n\nExploratory endpoints:\n\nPathological response of ablated tumor tissue， Correlation analysis between postoperative imaging (MRI\u002Fultrasound) features and recurrence risk.",[29,89,90,28],"Early Stage","Hormone Receptor Positive","2026-03-17",{"date":93,"type":36},"2026-03-19",{"date":95,"type":36},"2026-01-01",{"date":97,"type":22},"2031-12-31",{"name":42,"class":43},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":53,"minAge":4,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100600189","torque-device-evaluation-100600189","NCT07094256","Torque Device Evaluation","Evaluation of Novel Torque Device During Electrophysiology Study Procedure","Inclusion Criteria:\n\n* Pediatric patient (≤21 years of age)\n* Undergoing clinically-indicated electrophysiology study and\u002For ablation procedure\n\nExclusion Criteria:\n\n* Adult patient (\\>21 years)","21 Years",{"count":108,"type":22},25,[25],"This study will evaluate the safety and efficacy of a novel catheter torque device after the completion of a clinically-indicated electrophysiology study and\u002For ablation procedure in a pediatric patient. All electrophysiology studies and\u002For ablation procedures will be performed at the discretion of their primary cardiologist and will not be affected by this study protocol. The study protocol will commence once the attending electrophysiologist has completed all necessary intervention and testing and no further evaluation is required.",[112,28],"Electrophysiology Study","2026-02-19",{"date":115,"type":36},"2026-02-23",{"date":117,"type":36},"2025-08-25",{"date":119,"type":22},"2026-08-04",{"name":121,"class":43},"University of Minnesota",2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":122},"100589800","cellfx-nanosecond-pulsed-field-ablation-nspfa-cardiac-surgery-clamp-system-to-treat-atrial-fibrillation-100589800","NCT06959121","CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation","Pulse Biosciences' CellFX nsPFA Cardiac Surgery Clamp System for the Treatment of Atrial Fibrillation During Concomitant Cardiac Surgery","NANOCLAMP-AF","Inclusion Criteria:\n\n* Subject must be between 18 and 85 years of age\n* Subject is willing and capable of providing Informed Consent to undergo study procedures which include the potential for surgical AF ablation, and completion of follow-up visits as specified in the clinical study protocol\n* Subject has history of documented paroxysmal atrial fibrillation (AF that is intermittent and terminates within ≤ 7 days of onset) or persistent\u002Flongstanding persistent atrial fibrillation (AF that is continuous and sustains for \\> 7 days and requires intervention) within one year prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM), Holter monitor or telemetry strip from the study hospital or an outside physician\n* Subject is scheduled to undergo non-emergent cardiac surgical procedure(s) to be performed on cardiopulmonary bypass including open-heart surgery via sternotomy for one or more of the following: Mitral valve repair or replacement, Aortic valve repair or replacement, Ascending aortic aneurysms, Atrial Septal Defect (ASD)\u002FPatent Foramen Ovale (PFO) or Coronary artery bypass procedures\n* Left ventricular ejection fraction ≥ 30% (determined by echocardiography or cardiac catheterization performed within 60 days of enrollment as documented in patient medical history)\n* Subject has a life expectancy of at least 5 years\n* Subject currently lives within a reasonable commuting distance of the investigational site and plans to remain geographically stable through 12 month follow up\n\nExclusion Criteria:\n\n* Subject has an implantable electronic medical device. (i.e., pacemaker, implantable cardioverter-defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) or left atrial appendage (LAA) device\n* Subject has history or known to have LAA clot\n* Subject has a prosthetic heart valve\n* Stand- alone AF without indication(s) for concomitant Coronary Artery Bypass Graft (CABG) and\u002For valve surgery\n* Prior cardiac surgery including prior cardiac surgical ablation\n* Left Atrial diameter ≥ 6cm\n* Wolff-Parkinson-White syndrome or other Supra-Ventricular Arrhythmia, Atrioventricular (AV) nodal reentry\n* Documented history of persistent or long standing persistent atrial fibrillation longer than 10 years\n* Subjects requiring surgery other than CABG and\u002For cardiac valve surgery and\u002For atrial septal defect repair\u002FPFO and ascending aorta\n* Prior history of medical procedure involving instrumentation of the left atrium (e.g., previous ablation)\n* Subjects that are on an AAD for ventricular arrhythmia.\n* STS Predicted Risk of Mortality (STS PROM) of 10 or higher\n* Class III or IV New York Heart Association (NYHA) heart failure symptoms\n* Prior history of stroke within 6 months\n* Documented ST-segment elevation Myocardial Infarction (MI) within the 6 weeks prior to study enrollment\n* Need for emergent cardiac surgery (per sit-to-stand (STS) test definition)\n* Known carotid artery stenosis greater than 80%\n* Current diagnosis of active systemic infection\n* Severe peripheral arterial occlusive disease defined as claudication with minimal exertion\n* Renal failure requiring dialysis or hepatic failure (significant liver dysfunction with markedly significant elevation of liver enzymes, such as cirrhosis with decompensation, portal hypertension, or a history of hepatic failure)\n* A known drug and\u002For alcohol addiction\n* Mental impairment or other conditions that may not allow the subject to understand the nature, significance, and scope of the study\n* Pregnancy or desire to get pregnant within 12 months of the study treatment\n* Preoperative need for an intra-aortic balloon pump or intravenous inotropes\n* Subjects who have been treated with thoracic radiation\n* Subjects in current chemotherapy\n* Subjects on long-term treatment with oral or injected steroids (not including intermittent use of inhaled steroids for respiratory diseases)\n* Subjects with known hypertrophic obstructive cardiomyopathy\n* Subjects with known cold agglutinin\n* Subject has a contraindication to anticoagulation (e.g., a bleeding or clotting disorder such as Idiopathic Thrombocytopenic Purpura (ITP))\n* Solid organ or hematologic transplant, or currently being evaluated for an organ transplant\n* Body mass index \\> 45 kg\u002Fm2\n* Any diagnosed connective tissue disorder\n* Severe Chronic Obstructive Pulmonary Disease (COPD) per sit-to-stand (STS) test definition\n* Use of any other investigational drug, therapy, or device within 30 days before enrollment or concurrent participation in another research study","85 Years",{"count":133,"type":22},135,[25],"The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.",[137,138,139,28],"Atrial Fibrillation","Maze Procedure","AF",[63],"2026-01-09",{"date":143,"type":36},"2026-01-12",{"date":145,"type":36},"2025-10-23",{"date":147,"type":22},"2028-12",{"name":73,"class":74},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":131,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":181},"100611427","endo-epicardial-versus-endocardial-only-catheter-ablation-for-ischemic-driven-ventricular-tachycardia-episode-vt-100611427","NCT07240441","Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT)","Endo-ePIcardial Versus Endocardial Only Catheter Ablation for ISchemic Driven Ventricular Tachycardia (EPISODE VT) - Multicenter, Prospective, Randomized Trial","EPISODE_VT","Inclusion Criteria:\n\n* Status after myocardial infarction (minimum 3 months before inclusion in the study).\n* Documented post-infarction VT or VF.\n* Implantable ICD (at least 2 weeks before ablation) or CRT-D (at least 2 months before ablation).\n* A history of at least one from below:\n\n  1. One or more high energy interventions.\n  2. Three or more adequate antitachycardia pacing therapies, including one symptomatic.\n  3. Three or more episodes of VT in 24 hours (interrupted by ATP or shock) - electrical storm.\n  4. Sustained VT recorded on ECG with a cycle length longer than the ICD detection threshold.\n* Age between 18 and 85 years.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Obesity with BMI \\> 40 kg\u002Fm2.\n* Left ventricle ejection fraction \\\u003C 20%.\n* Pregnancy or breastfeeding.\n* Renal failure (eGFR \\\u003C 20 mL\u002Fmin\u002F1.73m2).\n* Fresh ballot thrombus in the left ventricle.\n* Suspicion of massive adhesions in the pericardium that may impede pericardial puncture.\n* Ablation of the post-infarction VT in the left ventricle in medical history.\n* Previous heart surgery.\n* Acute conditions that prevent ablation (including active infection, overt hyperthyroidism and others listed below).\n* Active neoplastic disease.\n* Heart failure with NYHA IV.\n* Life expectancy less than 12 months.",{"count":158,"type":22},220,[25],"The EPISODE VT trial is designed to compare efficacy and safety of two modalities for interventional treatment - endocardial ablation and endo-epicardial ablation in a population of patients with post myocardial infarction (ICD 10 - I25.2) ventricular tachycardias (ICD 10 - I47.2), who are protected by an implantable cardioverter-defibrilator (ICD) and meet study inclusion criteria.",[162,163,164,28],"Ventricular Tachycardias","Myocardial Infarction (MI)","Implantable Cardiac Defibrillator",[166,167,168,169,170,171],"ventricular tachycardia","myocardial infarction","epicardial access","pericardial sac puncture","ablation","implantable cardioverter defibrillator","2025-11-18",{"date":174,"type":36},"2025-11-20",{"date":176,"type":36},"2025-02-03",{"date":178,"type":22},"2030-11-30",{"name":180,"class":43},"MEDICOVER SP Z O.O.",9,{"id":183,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":185,"briefSummary":26,"conditions":186,"keywords":187,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":44},"100611308",{"count":21,"type":22},[25],[28,29],[31],"2025-11-15",{"date":174,"type":36},{"date":191,"type":22},"2025-12-01",{"date":40,"type":22},{"name":42,"class":43},{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":19,"enrollmentInfo":201,"targetDuration":4,"studyType":203,"phases":4,"briefSummary":204,"conditions":205,"keywords":210,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":44},"100565611","ablation-of-pulmonary-oligometastasis-combined-with-system-for-advanced-hepatocellular-carcinoma-100565611","NCT06644430","Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","Ablation of Pulmonary Oligometastasis Combined With System Compared System Therapy for Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases;\n2. presence of pulmonary oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of first-line systemic therapy for minimum of 3 months before ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) were included;\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. intermediate HCC;\n2. age \\\u003C 18 years or \\> 75 years;\n3. advanced HCC with more than five metastases;\n4. no response to Lenvatinib;\n5. metastases size \\> 5 cm;\n6. life expectancy less than 3 months.",{"count":202,"type":22},470,"OBSERVATIONAL","Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.",[206,207,208,28,209],"Advanced Hepatocellular Carcinoma","Lung Cancer","Oligometastasis","Systemic Therapy",[211,212,213,214,215,216,217,218],"Advanced hepatocellular carcinoma","Lenvatinib","Sorafeinib","Camrelizumab","Tislelizumab","Sintilimab","Toripalimab","Apatinib","2024-12-01",{"date":221,"type":36},"2024-12-03",{"date":223,"type":36},"2024-10-04",{"date":225,"type":22},"2025-12-30",{"name":227,"class":43},"Sun Yat-sen University",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":249,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":44},"100562952","the-comparison-of-tace-lenvatinib-with-tace-lenvatinib-ablation-for-intermediate-recurrent-hepatocellular-carcinoma-100562952","NCT06609850","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma: a Multicenter Randomized Control Study","Inclusion Criteria:\n\n1. 18-75 years;\n2. RHCC diagnosed by imaging;\n3. intermediate-stage RHCC (two to three lesions which at least one was \\>3 cm in size or more than three tumors);\n4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm;\n5. absence of extrahepatic metastasis or macrovascular invasion;\n6. Child-Pugh class A or B;\n7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE.\n8. life expectance \\>3 months;\n\nExclusion Criteria:\n\n1. under 18 years or over 75 years of age;\n2. primary intermediate-stage HCC;\n3. RHCC with more than six tumors, or single RHCC\n\n(5) RHCC \\>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;","75 Years",{"count":237,"type":22},116,[25],"Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.",[241,212,242,28,209],"Recurrent Hepatocellular Carcinoma","Local Therapy",[244,245,246,247,248],"Lenvatinb","Hepatocellular carcinoma","Microwave ablation","Radiofrequency ablation","Cryoablation",{"date":221,"type":36},{"date":251,"type":36},"2024-10-01",{"date":253,"type":22},"2028-10-30",{"name":227,"class":43},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":235,"enrollmentInfo":263,"targetDuration":4,"studyType":23,"phases":265,"briefSummary":266,"conditions":267,"keywords":269,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100555802","cpvi-with-modified-linear-ablation-versus-cpvi-in-patients-with-long-standing-persistent-atrial-fibrillation-sinus-100555802","NCT06516822","CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)","Circumferential Pulmonary Vein Isolation With Modified Linear Ablation Versus Circumferential Pulmonary Vein Isolation Only in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)","SINUS","Inclusion Criteria:\n\n1. 1\\. Patients with symptomatic LSPAF refractory to at least one antiarrhythmic drug; LSPAF will be defined as a sustained AF episode lasting ≥ 1 year;\n2. AF duration 1-3 years;\n3. Age 18 - 75 years;\n4. Left atrial diameter (LAD) 43-55 mm on long axis parasternal view;\n5. AF recorded within 3 years of enrollment;\n6. Patient willing and able to comply with protocol and sign informed consent\n\nExclusion Criteria:\n\n1. Paroxysmal atrial fibrillation;\n2. Persistent AF lasting \\\u003C 1 year or \\>3 years;\n3. Left atrial thrombosis;\n4. Patients with a history of catheter ablation for AF;\n5. Patients with severe structural heart disease (severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.);\n6. LAD \\> 55mm on long axis parasternal view;\n7. Left ventricular ejection fraction (LVEF) \\\u003C 40%;\n8. Patients with contraindications to low molecular weight heparin, warfarin or novel oral anticoagulants;\n9. One-stop procedure for AF ablation and left atrial appendage occlusion;\n10. Alcohol allergy or contrast agent allergy;\n11. Patients taking cephalosporin antibiotics within 72 hours prior to ablation;\n12. Pulmonary artery systolic pressure \\> 50mmHg;\n13. Patients with unstable angina pectoris;\n14. Patients who had undergone percutaneous coronary intervention (PCI) within 3 months;\n15. Patients who had undergone surgery within 6 months;\n16. Patients ready to receive heart transplantation;\n17. Patients with a history of thromboembolism within 6 months;\n18. Patients with diagnosed atrial myxoma;\n19. Patients with severe respiratory diseases;\n20. Patients with infectious diseases in active phase;\n21. Patients with poorly controlled systemic immune diseases;\n22. Patients with uncured malignant hematological diseases;\n23. Patients with uncured malignant solid tumors;\n24. Patients with untreated hypothyroidism or hyperthyroidism;\n25. Patients with severe liver dysfunction (elevation of transaminases \\[ALT or AST\\] \\>3 times the upper limit of normal range);\n26. Patients with end-stage renal failure requiring dialysis;\n27. Patients with other serious arrhythmias, such as ventricular tachycardia with hemodynamic instability;\n28. Pregnant and lactating women;\n29. Patients with psychiatric ailments;\n30. BMI \\\u003C 18.5 or ≥ 30kg\u002Fm2;\n31. Life expectancy \\\u003C 2 years;\n32. Patients unwilling or unable to give informed consent;\n33. Patients unwilling or unable to cooperate to complete follow-up.",{"count":264,"type":22},320,[25],"Catheter ablation has become as the first-line treatment for patients with symptomatic atrial fibrillation (AF). As the cornerstone of catheter ablation for AF, the safety and efficacy of circumferential pulmonary vein isolation (CPVI) have been confirmed. However, for persistent AF, especially for long-standing persistent AF (LSPAF), the recurrence rate is still high. Whether the ethanol infusion (EI) into the vein of Marshall (EI-VOM) and linear ablation could improve the success rate remains controversial.\n\nThe SINUS study is a prospective, multicenter, randomized trial, which is designed to compare the efficacy and safety between CPVI with modified linear ablation (CPVI-MLA) and CPVI only for the treatment of LSPAF.",[268,28],"Long-standing Persistent Atrial Fibrillation",[270,271,272,273],"long-standing persistent atrial fibrillation","circumferential pulmonary vein isolation","modified linear ablation","arrhythmia-free survival","2024-11-06",{"date":276,"type":36},"2024-11-08",{"date":278,"type":36},"2024-07-31",{"date":280,"type":22},"2027-12",{"name":282,"class":43},"The First Affiliated Hospital with Nanjing Medical University",10,{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":235,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":294,"conditions":295,"keywords":297,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":44},"100558423","ablation-of-oligometastasis-combined-with-lenvatinib-and-pd-1-inhibitor-for-advanced-hepatocellular-carcinoma-100558423","NCT06550921","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma","Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Multicenter, Prospective, Phase II Study","Inclusion Criteria:\n\n1. diagnosis of primary HCC, confirmed histologically or clinically according to the criteria of the American Association for the Study of Liver Diseases 20;\n2. presence of oligometastasis, the metastases found within three month of HCC diagnosis;\n3. metastases with limited five sites and no more two organs involved, with a maximum diameter of ≤5cm;\n4. receipt of Lenvatinib and PD-1 inhibitor as the first-line systemic therapy for a minimum of 3 months before study ablation, with controlled intrahepatic tumors and no progression of metastases. Controlled intrahepatic tumors were defined as those showing a partial or stable response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n5. undergone locoregional treatments, including transarterial artery chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC);\n6. classified as Child-Pugh class A or B and having an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n7. no history of other malignancies.\n8. life expectancy more than 3 months;\n9. agreed to participated in this clinical trial;\n10. Hemameba ≥3.0 x109\u002FL, neutrophil ≥1.5x109\u002FL, hemoglobin≥10.0 g\u002FL, platelet≥100x 109\u002FL, ALT; AST; bilirubin ≤1.5-fold normal, GFR≥60ml\u002Fmin.\n\nExclusion Criteria:\n\n1. recurrent HCC;\n2. advanced HCC Lenvatinib and PD-1 inhibitor treated with as second systemic therapy;\n3. age \\\u003C 18 years or \\> 75 years;\n4. advanced HCC with more than five metastases;\n5. no response to Lenvatinib;\n6. metastases size \\> 5 cm;\n7. life expectancy less than 3 months.",{"count":292,"type":22},60,[25],"Ablation has been an effective approach for treating intrathoracic metastases. However, for hepatocellular carcinoma with oligometastasis, ablation of metastases remains relatively unexplored.",[206,208,28,296,212],"Anti-PD1 Antibody",[244,215,216,214],"2024-08-08",{"date":300,"type":36},"2024-08-13",{"date":302,"type":36},"2024-08-01",{"date":304,"type":22},"2027-08-30",{"name":227,"class":43},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":16,"sex":314,"minAge":83,"maxAge":19,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":44},"100492932","tranberg-transperineal-mrus-fusion-laser--induced-thermal-therapy-for-men-with-prostate-cancer-100492932","NCT05698576","TRANBERG® Transperineal MR\u002FUS Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer","TRANBERG® Transperineal MR\u002FUS Focalyx Fusion Laser--Induced Thermal Therapy in the Office Setting Under Local Anesthesia","TPF-LITT","Inclusion Criteria:\n\n* Willing and able to sign informed consent\n* Subject is able and willing to complete all procedure and follow-up visits indicated in the protocol\n* Absence of urinary retention\n* Prostate volume: ≥ 18 and ≤ 100 cc, measured by transrectal ultrasound\n* Serum creatinine levels \\\u003C2 ng\u002Fdl and GFR \\> 45\n* Serum PSA levels \\\u003C 20 ng\u002Fml\n* Multiparametric prostate MRI with piRADS scores 3-5\n* Prostate volume: ≥ 18 and ≤ 100 cc, measured by MRI\n* Presence of Intermediate risk prostate cancer with a volume that is less than 1\u002F3 of the gland volume by MRI evaluation\n\nExclusion Criteria:\n\n* Post-void residual (PVR): \\> 250 mL or \\> 50% of voided volume\n* Previous prostate cancer intervention (Radiation therapy, brachytherapy, prostate cryoablation\n* Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury\n* Evidence of neurogenic bladder determined by urodynamics studies\n* Presence of Indwelling Foley catheter or on active regime of clean intermittent catheterization (CIC) in the prior 30 days\n* Active urinary tract infection determined by urinary cultures\n* SHIM score \\\u003C14\n* IPSS score \\>23\n* Acute prostatitis\n* Macroscopic hematuria without a known contributing factor\n* History of colorectal carcinoma with anterior perineal resection of rectum\n* History of pelvic radiation therapy or radical pelvic surgery\n* History of bladder neck contracture and\u002For urethral strictures within the 5 years prior to the informed consent date\n* Bladder stones\n* Medical contraindication for undergoing TPFLA surgery (eg, infection, coagulopathy, significant cardiac or other medical risk factors for surgery)\n* Diagnosed or suspected bleeding or coagulopathic disorder such as hemophilia, ITP, TTP\n* Medical contraindication to being subjected to local anesthesia","MALE",{"count":316,"type":22},20,[25],"This study is set up as a phase I prospective, single center, device interventional pilot study carried in office setting under local anesthesia. It will assess the tolerance and safety of target fusion ablation of prostate cancer tumors using Laser Induced Thermal Therapy (TFA-LITT) guided by fusion imaging in men 50 to 80 years of age with low to intermediate risk prostate cancer\n\nProstate Cancer is currently managed with in a discrete fashion where patients either enroll in active surveillance protocols (No intervention) or undergo full intervention via whole gland treatments - most commonly radical surgery or radiation. These treatments have not shown definitive gains in all cause survival and not uncommonly harbor undesirable adverse effects, most notably: impotency and incontinence. Such events elicit significant and noticeable changes on a male lifestyle and for most prostate cancer tumors are considered overtreatment. This study aims to evaluate the use of TFA-LITT in the office setting under local anesthesia - greatly decreasing patient perioperative surgical risk - focused on the organ sparing cancer lesion ablation, where organ function is preserved.\n\nThe fundamental objective is to determine the tolerance and safety of TFA-LITT in men with low to intermediate risk prostate cancer, successful performed in the outpatient office-based setting under local anesthesia directed by fusion imaging. Secondary objectives include: 1-Biopsy proven cancer control of ablated areas 12 months after procedure; 2-Uroflowmetry and urinary function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 3- Sexual function Patient Reported Outcome Measures (PROMs) at one, three, six, nine and 12 months; 4- MRI changes of ablated area one, three and 12 months after TFA-LITT; 5- Absence or presence of ejaculation after TFA-LITT.",[320,321,322,323,324,325,326,327,28],"Prostate Cancer","Adverse Effects Surgery","MRI","Ultrasound","Sexual Function Disturbances","Urinary Incontinence","Urinary Function Disorders","Prostate Biopsy","2023-01-24",{"date":330,"type":36},"2023-01-26",{"date":332,"type":36},"2022-03-16",{"date":334,"type":22},"2033-01-30",{"name":336,"class":43},"Urological Research Network, LLC"]